SIGNPATH PHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 2
- Market Cap
- -
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Phase 1
Recruiting
- Conditions
- Glioblastoma
- Interventions
- Drug: Treatment Period 1Drug: Treatment Period 2Drug: Treatment Period 3Drug: Treatment Period 4a
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- SignPath Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05768919
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins University/Johns Hopkins Hospital, Baltimore, Maryland, United States
A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer
Phase 1
Completed
- Conditions
- Patients w/Advanced Cancer That Failed Std of Care Therapy
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- SignPath Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02138955
- Locations
- 🇦🇹
3 Medicizinische Universitatsklinik Hematologie,Internistische Onkologie, Salzburg, Austria
🇦🇹3. Medizinische Universitatesclinik, Haematologie, Internistische Onkologie, Salzburg, Austria
Evaluation of Liposomal Curcumin in Healthy Volunteers
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- SignPath Pharma, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01403545
- Locations
- 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
© Copyright 2025. All Rights Reserved by MedPath